CRP and metabolic dysfunction-associated steatohepatitis: Animal models targeting a specific disease pathology (diabetic, hypertensive, hyperlipidemic/cholesterolemic, and NASH) demonstrated improvements in biomarkers and mechanisms that are translatable to human studies, such as lipids, glucose, blood pressure, renin, inflammatory markers (CRP, IL-6), and hepatic and cardiovascular markers.